期刊文献+

PI-RADS v2.0在前列腺癌1.5T多参数磁共振成像诊断中的临床应用

Clinical Application of PI-RADS v2.0 in the Diagnosis of Prostate Cancer with 1.5T Multi-parameter Magnetic Resonance Imaging
下载PDF
导出
摘要 目的探析PI-RADS v2.0在前列腺癌1.5T多参数磁共振成像诊断中的应用效果。方法选取88例前列腺癌患者,均接受MP-MRI检查,根据检查所得图像进行PI-RADS v2.0评分,以病理结果为金标准,分析其对前列腺癌的诊断效能。结果PI-RADS v2.0的一致性较好,Kappa值为0.83;528个前列腺分区接受T2WI序列诊断发现阳性分区294个,阴性234个,接受DWI序列诊断共发现阳性分区273个,阴性255个,接受T2WI+DWI+DCE序列联合诊断共发现阳性分区276个,阴性252个。结论PI-RADS v2.0评分在前列腺癌诊断中的应用效果较好,具有临床推广价值。 Objective To explore the application effect of PI-RADS v2.0 in 1.5T multi-parameter magnetic resonance imaging diagnosis of prostate cancer.Methods A total of 88 patients with prostate cancer were selected,all received MP-MRI examination,and PI-RADS v2.0 was scored according to the obtained images.The pathological results were used as the gold standard to analyze its diagnostic efficacy for prostate cancer.Results The consistency of PI-RADS v2.0 is good,and the Kappa value is 0.83.T2WI sequence diagnosis of 528 prostate sections revealed 294 positive sections and 234 negative sections.A total of 273 positive partitions and 255 negative partitions were found by DWI sequence diagnosis.A total of 276 positive partitions and 252 negative partitions were found in the combined diagnosis of T2WI+DWI+DCE sequence.Conclusion The application effect of PI-RADS v2.0 score in the diagnosis of prostate cancer is good,and it has clinical promotion value.
作者 袁迎弟 袁丽娟 YUAN Yingdi;YUAN Lijuan(Ganzhou District People’s Hospital,Zhangye,Gansu 734000;Jiugang Hospital,Jiayuguan,Gansu,735100)
出处 《智慧健康》 2022年第23期5-8,25,共5页 Smart Healthcare
关键词 前列腺影像 数据系统 前列腺癌 多参数磁共振成像 应用效果 Prostate imaging Data system Prostate cancer Multiparameter magnetic resonance imaging Application effect
  • 相关文献

参考文献10

二级参考文献105

  • 1张鑫,邓勋伟,徐良洲,余永强.超高b值小视野DWI对前列腺癌的诊断价值[J].临床放射学杂志,2020,39(9):1877-1881. 被引量:5
  • 2SiegelRL, MillerKD, JemalA. Cancer statistics, 2016[J]. CA Cancer J Clin, 2016, 66(1): 7-30.
  • 3ChenW, ZhengR, BaadePD, et al. Cancer statistics in China, 2015[J]. CA Cancer J Clin, 2016, 66(2):115-132.
  • 4ChopraS, RashidP. Management of castration-resistant (advanced) prostate cancer (CRPC): rationale, progress and future directions[J].Aust Fam Physician, 2015, 44(5): 302-305.
  • 5MolinaA, BelldegrunA. Novel therapeutic strategies for castration resistant prostate cancer: inhibition of persistent androgen production and androgen receptor mediated signaling[J]. J Urol, 2011, 185(3):787-794.
  • 6ScherHI, FizaziK, SaadF, et al. Increased survival with enzalutamide in prostate cancer after chemotherapy[J]. N Engl J Med, 2012, 367(13):1187-1197.
  • 7PientaKJ. Preclinical mechanisms of action of docetaxel and docetaxel combinations in prostate cancer[J]. Semin Oncol, 2001, 28(4Suppl 15):3-7.
  • 8PallerCJ, AntonarakisES. Cabazitaxel: a novel second-line treatment for metastatic castration-resistant prostate cancer[J]. Drug Des Devel Ther, 2011, 5:117-124.
  • 9BertholdDR, PondGR, SobanF, et al. Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer: updated survival in the TAX 327 study[J]. J Clin Oncol, 2008, 26(2):242-245.
  • 10OudardS, BanuE, BeuzebocP, et al. Multicenter randomized phase II study of two schedules of docetaxel, estramustine, and prednisone versus mitoxantrone plus prednisone in patients with metastatic hormone-refractory prostate cancer[J]. J Clin Oncol, 2005, 23(15):3343-3351.

共引文献345

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部